The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis-Reference-Cited by-同舟云学术

The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis

Published:2014-06-06 Issue:3 Volume:35 Page:953-966
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Barreyro Fernando J.¹²,Holod Silvia²,Finocchietto Paola V.²,Camino Alejandra M.³,Aquino Jorge B.⁴,Avagnina Alejandra⁵,Carreras María C.²,Poderoso Juan J.²,Gores Gregory J.⁶

Affiliation:

1. Laboratory of Microbiology; Faculty of Chemical and Natural Sciences; National University of Misiones; CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas); Posadas Argentina

2. Laboratory of Oxygen Metabolism; University Hospital; University of Buenos Aires; Buenos Aires Argentina

3. Laboratorio de Morfometría; DIM Clinica Privada; Buenos Aires Argentina

4. Liver Unit; School of Medicine; Austral University; Buenos Aires Argentina

5. Department of Pathology; University Hospital; University of Buenos Aires; Buenos Aires Argentina

6. Division of Gastroenterology and Hepatology; Mayo Clinic College of Medicine; Rochester MN USA

Funder

Agencia Nacional para la Promocion Cientifica y Tecnologica

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12570/fullpdf

Reference70 articles.

1. A position statement on NAFLD, NASH based on the EASL, special conference;Ratziu;J Hepatol,2009

2. Nonalcoholic fatty liver disease;Angulo;N Engl J Med,2002

3. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology;Chalasani;Gastroenterology,2012

4. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults;Vernon;Aliment Pharmacol Ther,2011

5. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis;Feldstein;Gastroenterology,2003

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Targeting cell death in NAFLD: mechanisms and targeted therapies;Cell Death Discovery;2024-09-07

3. Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease;Biochemical and Biophysical Research Communications;2024-09

4. Caspase inhibitors: a review on recently patented compounds (2016–2023);Expert Opinion on Therapeutic Patents;2024-08-29

5. Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease;Journal of Clinical and Translational Hepatology;2024-07-31